Abstract:Gout arthritis (GA) is a common and curable type of inflammatory arthritis that has been attributed to a combination of genetic, environmental and metabolic factors. Chronic deposition of monosodium urate (MSU) crystals in articular and periarticular spaces as well as subsequent activation of innate immune system in the condition of persistent hyperuricemia are the core mechanisms of GA. As is well known, drugs for GA therapy primarily consists of rapidly acting anti-inflammatory agents and life-long uric acid lowering agents, and their therapeutic outcomes are far from satisfactory. Although MSU crystals in articular cartilage detected by arthrosonography or in synovial fluid found by polarization microscopy are conclusive proofs for GA, the exact molecular mechanism of NLRP3 inflammasome activation in the course of GA still remains mysterious, severely restricting the early diagnosis and therapy of GA. On the one hand, the activation of Nod-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome requires nuclear factor kappa B (NF-κB)-dependent transcriptional enhancement of NLRP3, precursor (pro)-caspase-1 and pro-IL-1β, as well as the assembly of NLRP3 inflammasome complex and sustained release of inflammatory mediators and cytokines such as IL-1β, IL-18 and caspase-1. On the other hand, NLRP3 inflammasome activated by MSU crystals is particularly relevant to the initiation and progression of GA, and thus may represent a prospective diagnostic biomarker and therapeutic target. As a result, pharmacological inhibition of the assembly and activation of NLRP3 inflammasome may also be a promising avenue for GA therapy. Herein, we first introduced the functional role of NLRP3 inflammasome activation and relevant biological mechanisms in GA based on currently available evidence. Then, we systematically reviewed therapeutic strategies for targeting NLRP3 by potentially effective agents such as natural products, novel compounds and noncoding RNAs (ncRNAs) in the treatment of MSU-induced GA mouse models. In conclusion, our present review may have significant implications for the pathogenesis, diagnosis and therapy of GA.

Recent advances in the treatment of gout with NLRP3 inflammasome inhibitors

Role of NLRP3 in the pathogenesis and treatment of gout arthritis

Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout

Immune and inflammatory mechanisms and therapeutic targets of gout: An update

Scaffold hopping-driven optimization for the identification of NLRP3 inhibitors as potential gout therapeutics

Recent Advances in Gout Drugs

Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease

Cichoric Acid Ameliorates Monosodium Urate-Induced Inflammatory Response by Reducing NLRP3 Inflammasome Activation via Inhibition of NF- k B Signaling Pathway

Cichoric Acid Ameliorates Monosodium Urate-Induced Inflammatory Response by Reducing NLRP3 Inflammasome Activation via Inhibition of NF-kB Signaling Pathway

A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout

Targeting Toll-like receptor 4 (TLR4) and the NLRP3 inflammasome: Novel and emerging therapeutic targets for hyperuricaemia nephropathy

Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential

Inflammatory Response to Regulated Cell Death in Gout and Its Functional Implications

Integration of Established Therapies, Emerging Treatments, and Lifestyle Interventions

Purinergic Signaling in the Regulation of Gout Flare and Resolution

Mechanistic and therapeutic insights into the function of NLRP3 inflammasome in sterile arthritis

Synthesis and Biological Evaluation of Novel Chlorogenic Acid-Apigenin Conjugates as Anti-acute Gout Agents

The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies

Advancements in the study of IL-6 and its receptors in the pathogenesis of gout

Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders